Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now capture and remove embolic particles during angioplasty procedures.
The Angioslide PROTEUS™ device addresses the unmet need for an easy-to-use, efficient, and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use, and is marketed throughout Europe.
A multi-center trial conducted at leading European medical centers has demonstrated the device's ability to remove embolic particles and function as a PTA balloon.
Angioslide’s innovative, pioneering team is committed to bringing our ECA technology to the forefront of the peripheral vascular disease treatments of various vascular beds.